Reviral's series A provides runway to move RSV candidate into the clinic

LONDON – UK start-up company Reviral Ltd. has attracted one of the global stars of nucleoside chemistry and antiviral drugs to its board, as it prepares the ground for a series A later this year to raise £4 million to £5 million (US$6.8 million to US$8.5 million).